Pre-earnings brief
Reports
Wed, Oct 28, 2026
Est. EPS
—
Est. revenue
—
Implied move
±8.2%
EPS beat rate
88%
Biogen Inc. (BIIB) is a biotechnology company focused on developing therapies for neurological diseases. With a market cap of $33 billion, it plays a crucial role in the healthcare sector, particularly in treating conditions like Alzheimer's and multiple sclerosis.
Last quarter
In Q2-2026, Biogen reported an impressive EPS of $3.60, significantly exceeding estimates by 229%. The stock rose 1.76% the following day, reflecting positive investor sentiment.
EPS beat streak
5Q
EPS beat rate
88%
Avg EPS surprise
+41.34%
Avg 1-day reaction
+1.61%
Overall, investors are optimistic about Biogen's upcoming earnings, especially after strong performance in previous quarters. However, there is uncertainty regarding revenue figures and pipeline developments.
Bull case
If Biogen continues its trend of beating EPS estimates, it could see a strong stock price increase, driven by positive sentiment around its drug pipeline.
Bear case
Conversely, if the company fails to meet expectations or provides disappointing updates on its drug pipeline, it could lead to a decline in stock price.
The print will turn on these.
Q1
What will the EPS be for Q3-2026?
Given Biogen's history of beating EPS estimates, this figure will be crucial in determining market reaction.
Q2
What updates will be provided on the drug pipeline?
Investors will closely watch for any news that could impact future revenue and growth prospects.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±9.4%
Why consensus could be wrong
The Street may underestimate the impact of Biogen's recent drug trial successes, which could lead to higher-than-expected revenue growth.
Supporting evidence
Biogen has consistently beaten EPS estimates, indicating strong operational execution.
The options market is pricing in a significant move, suggesting that traders expect volatility that could favor the upside.
Recent insider activity shows mixed signals, but no large sell-offs, which may indicate confidence in the company's future.
Key risk
If drug pipeline updates reveal significant advancements, it could shift investor sentiment dramatically.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around Biogen's ability to maintain its strong earnings performance while navigating challenges in its drug pipeline.
Bull confirmed if
An EPS of $4.00 or higher would confirm the bull case and suggest strong operational performance.
Bear confirmed if
An EPS below $2.50 would confirm the bear case and raise concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±8.23%
Historical Avg
±3.0%
The options market is pricing in a significant potential move for Biogen's stock, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±8.2% while BIIB has averaged ±3.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
23.0%
Smart-money positioning from the most recent 13F filings.
Institutional
99.53%
of float
Insider
0.19%
of float
Holders
1,486
institutions
Top Holders· as of Jun 2026
FMR, LLC
18,217,239 sh · $4.0B
12.33%
42.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Biogen beats expectations, history suggests the stock could rise by around 1.86%, confirming ongoing investor confidence.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
If Biogen misses expectations, history suggests a potential decline of around 0.12%, leading to increased scrutiny of its future prospects.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
6
4 buys·2 sells
Members
3
House only
Est. Notional
$69,006.00–$210,000.00
disclosed dollar ranges
Most Active Members
4 trades
The lines on the call that would change the story.
Blackrock Inc.
15,985,736 sh · $3.6B
10.82%
0.1%
Primecap Management Company
15,154,606 sh · $3.4B
10.26%
2.7%
Vanguard Capital Management LLC
9,651,117 sh · $2.1B
6.53%
1.2%
State Street Corporation
7,344,327 sh · $1.6B
4.97%
2.5%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Mixed
1 trade
Net selling
1 trade
Net buying
Recent Transactions
Traded Aug 18, 2026 · disclosed Sep 1, 2026
$1,001.00–$15,000.00
Traded Jun 5, 2026 · disclosed Jul 2, 2026
$1,001.00–$15,000.00
Traded Jun 2, 2026 · disclosed Jul 7, 2026
$15,001.00–$50,000.00
Traded May 12, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Traded May 11, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.